Previous Close | 0.6224 |
Open | 0.6223 |
Bid | 0.6000 x 1300 |
Ask | 0.6198 x 2200 |
Day's Range | 0.5900 - 0.6280 |
52 Week Range | 0.3100 - 3.7200 |
Volume | |
Avg. Volume | 419,043 |
Market Cap | 27.983M |
Beta (5Y Monthly) | -0.38 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.8290 |
Earnings Date | Nov 09, 2022 - Nov 14, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 1.84 |
Subscribe to Yahoo Finance Plus to view Fair Value for OPGN
Total Q2 2022 revenues of $1.0 million with product sales a key growth driverFirst two commercial customer contracts for Acuitas AMR Gene Panel signed in June and July 2022Requested additional 180-day period to regain compliance with Nasdaq minimum bid price ruleManagement conference call scheduled for August 11th, 2022, at 4:30 p.m. EDT ROCKVILLE, Md., Aug. 11, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of mol
ROCKVILLE, Md., July 28, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its second quarter 2022 financial results after the close of the U.S. financial markets on Thursday, August 11th, 2022. OpGen’s management team will host a live conference call and audio webcast at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide an update on business activities. Conference
Collaborators aim to develop and evaluate computation tools, including predictive models for whole genome sequencing-based antibiotic susceptibility testing (wgsAST)Ares plans to strategically expand its proprietary AMR knowledgebase ARESdb with data collected during the collaborationAres to deploy the commercial AREScloud web application at UZ Leuven to support pathogen typing, AMR characterization and outbreak analysis ROCKVILLE, Md., July 26, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN